The Manila Times

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT. Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1 ...

Viking outlines 52-week VANQUISH extension and plans oral VK2735 phase III start in Q4 2026

Q1 2026 Management View Brian Lian said the quarter’s operational focus was advancing VK2735 across multiple Phase III-enabling paths, stating, "we made significant progress with our obesity franchise ...
The Barre-Montpelier Times Argus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
ascopubs.org

Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium

Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized ...
ascopubs.org

Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects

The way late-onset toxicities are managed can affect trial outcomes and participant safety. Specifically, participants often might not have completed their entire follow-up period to observe any ...